Published: 2016-12-29

Characteristics of Regulatory T cells

Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Tregs regulatory T cells autoimmunity cancer


Regulatory T cells (Tregs) is heterogenic subpopulation of T cells that is able to suppress function of effector cells during the immune response. Among them are natural (nTreg) and induced Treg (Tr1, Th3, CD4+CD25-). CD25, CD45Ro, CD152, GITR, LAG-3, several adhesion molecules, chemokine receptors as well as Toll-like receptors are present on the surface of Treg. Mechanism of suppression used by nTreg is not completely understood.


Download data is not yet available.


  1. Koczorowski M, Jutel M. Human T Regulatory Cells: On the Way to Cognition. Arch. Immunol. Ther. Exp. 2013; 61:229–236
  2. Gershon RK, Konodo K. Cell interaction in the induction of tolerance: the role of thymic lymphocytes. Immunology. 1970; 18: 723–737
  3. Ruhnau J, Schulze J, von Sarnowski B, Heinrich M, Langner S, Pötschke, Wilden A, Kessler Ch, Bröker BM, Vogelgesang A, Dressel A. Reduced Numbers and Impaired Function of Regulatory T cells in Peripheral Blood of Ischemic Stroke Patients. Mediators of Inflammation. 2016; 2016, Article ID 2974605, 9 pages.
  4. Miyara M, Sakaguchi S. Human FoxP3+ CD4+ regulatory T cells: their knows and unknows. Immunology and Cell Biology. 2011; vol.89, no. 3, pp. 346–351.
  5. Antony PA, Restifo NP. CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2. J Immunother. 2005; 28(2): 120–128.
  6. Whiteside T L. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012; 22(4): 327–334.
  7. Zoltán Fehérvári Z, Sakaguchi S. A paragon of self-tolerance: CD25+CD4+ regulatory T cells and the control of immune responses. Arthritis Res Ther. 2004; 6:19–25.
  8. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic selftolerance. J Immunol. 1999; 162:5317–5326.
  9. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002; 16:311–323.
  10. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG: B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol. 2001, 2:1126–1132.
  11. Wing K, Suri-Payery E, Rudin A. CD4+CD25+-Regulatory T Cells from Mouse to Man. Scandinavian Journal of Immunology. 2005;62:1–15.
  12. Whiteside TL. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther. 2014 October; 14(10): 1411–1425.
  13. Takahashi T, Kuniyasu Y, Toda M et al. Immunologic selftolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969–80.
  14. Mercer F, Unutmaz D. The Biology of FoxP3: A Key Player in Immune Suppression during Infections, Autoimmune Diseases and Cancer. Adv Exp Med Biol. 2009; 665: 47–59.
  15. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1): 20–21.
  16. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a model of immune dysregulation. Curr Opin Allergy Clin Immunol. 2002; 2(6):481–487.
  17. Ryba M. Myśliwska J. Biologia naturalnych limfocytów regultorowych CD4+CD25+. Postępy Biologii Komórki. 2006; 33(3):427–436.
  18. Baecher-Allan C. Wolf E, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin. Immunol. 2004; 16:89–97.
  19. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25 T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001; 193: 1285–1294
  20. Budna J. Kaczmarek M. Sikora J. Znaczenie komórek T regulatorowych w rozwoju tolerancji na nowotwór. Postępy Biologii Komórki. 2011; 38 (2):283–295).
  21. Śledź-Gawrońska B. Rola limfocytów T regulatorowych CD4+CD25+ w rozwoju zaburzeń o podłożu immunologicznym. Journal of Laboratory Diagnostic. 2010; 46(2):147–153.
  22. Yang H, Qui L, Chen G. Proportional change of CD4+CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients. Fertil Steril. 2008; 89:656–661.
  23. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Exley M, Wilson B, Porcelli S, Maclaren M. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002; 109: 131–140.
  24. Brusko TM, Wasserfall CH, Clare-Salzlerm MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54: 1407–1414.
  25. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, Garcia C, Waldmann H, Bach JF, Chatenoud L. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005; 54: 1415–1422.
  26. Ehrenstein MR, Evan JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-? therapy. J Exp. Med. 2004; 200: 277–285.
  27. Viglietta V, Baecher. Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199: 971–979.
  28. Zou W. Regultory T cells, Tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295–307.
  29. Curiel TJ. Treg and rethinking cancer immunotherapy. J Clin Invest. 2007; 117: 1167–1174.
  30. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol. 2008 April; 20(2): 241–246.
  31. Sato E, Olson SH, Ahn J, Budny B, Nishikawa H, Qian F. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005; 102: 18538–18543.
  32. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25: 267–296.

How to Cite

Frydrychowicz M, Boruczkowski M, Kolecka-Bednarczyk A, Jenek R, Rosołowska J, Pluto-Prądzyńska A, Dworacki G. Characteristics of Regulatory T cells. JMS [Internet]. 2016Dec.29 [cited 2021Jan.27];85(4):323. Available from: